BDKRB1 and Parkinson disease: Niewiarowska-Sendo et al. (2016) found that the B1R agonist des-Arg10-kallidin enhanced reactive oxygen species (ROS) and NO levels and accelerated PD process (Niewiarowska-Sendo et al., 2016), while the B2R agonist BK induced the production of tumor necrosis factor-α (TNF-α), leading to cell death in PD (Niewiarowska-Sendo et al., 2016).